Pharsight

Lumryz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10736866 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11602512 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10973795 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11602513 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11400065 AVADEL CNS Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
Jul, 2037

(13 years from now)

US11000498 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10952986 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11065224 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11504347 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US11052061 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10272062 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Jul, 2037

(13 years from now)

US10925844 AVADEL CNS Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
Feb, 2040

(16 years from now)

US11583510 AVADEL CNS Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
Feb, 2042

(18 years from now)

Lumryz is owned by Avadel Cns.

Lumryz contains Sodium Oxybate.

Lumryz has a total of 13 drug patents out of which 0 drug patents have expired.

Lumryz was authorised for market use on 01 May, 2023.

Lumryz is available in for suspension, extended release;oral dosage forms.

Lumryz can be used as treatment of narcolepsy and associated disorders and symptoms using a composition comprising gamma-hydroxybutyrate once daily, treatment of narcolepsy-related cataplexy or excessive daytime sleepiness using a single daily, bedtime dose of a gamma-hydroxybutyrate formulation, treatment of narcolepsy-related cataplexy or excessive daytime sleepiness using a once-daily pharmaceutical formulation comprising an oxybate, treatment of a disorder treatable with gamma-hydroxybutyrate using a single, daily dose of a gamma-hydroxybutyrate formulation, treatment of narcolepsy using a dose proportional, oral pharmaceutical composition comprising gamma-hydroxybutyrate once daily, treatment of narcolepsy, cataplexy or excessive daytime sleepiness using a once-nightly gamma-hydroxybutyrate formulation.

The generics of Lumryz are possible to be released after 07 February, 2042.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 1, 2030
New Product (NP) May 1, 2026

Drugs and Companies using SODIUM OXYBATE ingredient

Market Authorisation Date: 01 May, 2023

Treatment: Treatment of narcolepsy-related cataplexy or excessive daytime sleepiness using a single daily, bedtime dose of a gamma-hydroxybutyrate formulation; Treatment of narcolepsy-related cataplexy or excess...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

LUMRYZ family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic